Fluticasone Furoate/Vilanterol Use Trends and Characteristics in Patients With Obstructive Airway Disease: A Real-World Study of 10,374 Patients From India

Introduction Obstructive Airway Diseases (OADs) are the leading cause of death among chronic respiratory diseases worldwide, and novel therapies are direly needed. Fluticasone furoate/vilanterol (FF/Vi) (100/25 µg) is the first once-daily ICS/uLABA marketed in India for COPD since 2021. Considering...

Descripción completa

Detalles Bibliográficos
Autores principales: Prabhudesai, Prahlad, Singh, Bhanu P, Agrawal, Gyanendra, Singh, Ashok Kumar, Jadhav, Amit Y, Patil, Saurabh R, Bhagat, Sagar, Patil, Saiprasad, Barkate, Hanmant
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cureus 2023
Materias:
Pulmonology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10008380/
https://www.ncbi.nlm.nih.gov/pubmed/36919064
http://dx.doi.org/10.7759/cureus.34825

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10008380/
https://www.ncbi.nlm.nih.gov/pubmed/36919064
http://dx.doi.org/10.7759/cureus.34825

Ejemplares similares